, although the increase was not always statistically significant. We report here the findings of a case control study carried out in New South Wales, Australia, designed to examine these relationships.
A number of recent studies have reported on the relationship between past oral contraceptive use and malignant melanoma (Beral et al., 1977; Ramcharan et al., 1981; Adam et al., 1981; Kay, 1981; Bain et al., 1982; Holly et al., 1983) . Most reported a weak association or none at all for melanoma and ever having used oral contraceptives. In contrast, however, all four which examined data on prolonged oral contraceptive use reported an increased risk associated with long term pill use (Beral et al., 1977; Adam et al., 1981; Bain et al., 1982; Holly et al., 1983) , although the increase was not always statistically significant. We report here the findings of a case control study carried out in New South Wales, Australia, designed to examine these relationships.
Methods
The study design has been described elsewhere (Beral et al., 1982 contraceptive use is closely correlated with the time since first taking the pill, we examined the data simultaneously for these two factors. The only group in which there was a consistently increased risk of melanoma was in those who had begun taking the pill at least 10 years before, and who had taken it for a total duration of 5 years or longer (RR=1.5, 95% confidence interval 1.03 to 2.14). Roughly similar relationships were found for "new" cases and "old" cases, as is shown in Table  II , and so most analyses pool the two groups. Our other analyses of these data have related melanoma to a number of factors (Beral et al., 1982 (Beral et al., , 1983 . We therefore stratified the findings for oral contraceptives by a large number of possible confounding factors. After adjusting for marital status, hair colour, skin colour, eye colour, country of birth, number of moles on the body, educational status, exposure to fluorescent light, history of cholasma, extent of outdoor activity at ages 10, 20, 30 and 40 years, and history of sunburning various parts of the body, the relative risks associated with pill use for 5 years or more which began at least 10 years ago fluctuated between 1.43 and 1.58 and remained statistically significantly elevated. There was no significant difference in the site of the lesion, the tumour thickness nor the tumour type in women who had used the pill and those who had not (Table III) .
Data on the use of other female sex hormones are shown in Table IV . The numbers reported to have ever used any of these is small, but the proportions of cases who reported that they used each was higher than the corresponding figures for the controls. The RRs and 95% confidence intervals for use of hormones to regulate periods was 1.9 (0.85-4.12). for hormones replacement therapy 1.4 (0.78-2.61) and for hormones to suppress lactation 1.3 (0.92-1.82).
Data on oral contraceptive use had been recorded for old cases on the melanoma clinic records before this survey began. The findings from our special survey agreed well with the distribution of duration of contraceptive use recorded in the clinic notes (Table V) . Furthermore, data from the clinic records on oral contraceptive use in the 87 women who were eligible but not interviewed in this survey, showed that their contraceptive use was also similar to that of the other women (Table V) . (26) 74(100) 148(100) 213(100) 424(100)
Discussion
The findings presented here indicate after a lag of 10 years oral contraceptive use for a total of 5 years or longer was associated with a 50% increase in risk (RR= 1.5, 95% confidence limits 1.03-2.14). This relationship persisted after adjusting for a number of potential confounding factors, including complexion, sunbathing activities, occupation and education.
Our data on oral contraceptive use are unlikely to be biased. For old cases they agree closely with that which was recorded in the melanoma clinic records before this survey began. Furthermore, the distribution of oral contraceptive use in the 87 women who had died, could not be traced, or were not interviewed for a number of other reasons was similar to that of those who were interviewed. Only limited information about brand of oral contraceptive was collected, and no marked associations were noted.
These Australian findings on the relationship between oral contraceptives and other hormones are in general consistent with reports from the UK and USA. All studies which have examined for an association with long term pill use or for a possible (Beral et al., 1983) . Both these factors are widely accepted as being important determinants of melanoma. Data on the use of female sex hormones, other than oral contraceptives, also tends to show a weak association with melanoma. In California the relative risk associated with other oestrogen use was 1.8 (Beral et al., 1977) ; in Washington State it was approximately 1.0 (Holly et al., 1983) ; in Percentages in parentheses. England, 1.4 (Adam et al., 1981) , and in our study the figure was 1.6. While none is statistically significant, all except for the Washington data show a consistent increase in risk. While oral contraceptives and other exogenous sex hormones are clearly not major determinants of melanoma, the accumulating evidence suggests that they may increase the risk of disease. If, as our data and that of others suggest, a lag period of 10 years or more is involved, it may still be several decades before the effect of oral contraceptives on malignant melanoma can be properly evaluated.
